Tanja Obradovic, Senior Advisor of Oncology Drug Development at HopeAI, Consultant, Oncology Drug Development at Arc Nouvel Clinical Development Consulting, and Oncology Medical Strategy Advisor at Mercurial AI, shared a post on LinkedIn:
“I’m happy to share that I’m starting a new position as Senior Advisor, Oncology Drug Development at HopeAI!
Delighted to be part of the outstanding HopeAI team, contributing to innovative AI solutions for clinical cancer drug development as Oncology Medical Strategy Advisor.
HopeAI team drives toward new horizons for AI tools that improve trial design, decision making across program and pipeline, establishment of clinically meaningful thresholds for end-points, with absolute commitment to achieving the best for patients, delivering faster cancer drugs at the bedside. Tackling these critical elements of new cancer drug development is truly at the forefront of AI evolution as a powerful tool for Biotech and Pharma, expanding oncology clinical portfolios.
Looking forward to expanding AI Solutions offered by an outstanding team, including just established PURE Evidence that enables improved trial design and establishment of relevant end points based on synthesized information across hundreds of thousands of data sources relevant for specific tumor type.”
More posts featuring Tanja Obradovic.